RLT-PSMA
Radioligand therapy prostate-specific membrane antigen
Advertisement
The new indication will improve access to imaging for approximately 32,000 candidates for radioligand therapy in the US.
Scott Tagawa, MD, MS, FACP, shares what needs to happen for radionuclide therapy to make its way into the community setting.
Scott Tagawa, MD, MS, FACP, highlights what clinicians must know prior to recommending Lutetium-177–PSMA-617 to patients.
Dr. Ulaner highlights the line(s) of therapy in which novel RLT-PSMA agents are being developed.
Dr. Ulaner explains the data that led to the FDA approval of 177Lu-PSMA-617 and the safety profile of this drug.
Moffitt Cancer Center developed the first PRO measure for patients receiving RNT to guide treatment and improve QoC.
While PSMA-RLT is typically used during later disease stages, patients in earlier disease stages may benefit as well.
Implementing a genetic testing model for prostate cancer patients can improve detection rates for actionable mutations.
A study sought to assess organoids and short-term ex vivo cultures of prostate cancer.
Researchers developed the first validated risk model for discerning personalized prostate cancer risks.
A risk score can predict prostate cancer in men of African ancestry.
A greater family history of prostate cancer is associated with a lower risk of mortality.
Dr. Jacqueline Brown talks about current challenges and advances in phenotypic precision medicine and treatment strategies.
Researchers analyzed 18F-PSMA-1007 PET/CT radiomics for their efficacy in determining tumor malignancy in prostate cancer.
An auto-segmentation model for PSMA PET-delineated tubarial glands has been recently examined.
A recent study analyzed the efficacy of 68Ga-PSMA PET/CT in patients with a history of prostate cancer who have BCR.
The single-center, single-arm phase 1/2 AlphaBet trial will evaluate radium-223 & [177Lu]Lu-PSMA-I&T in patients with mCRPC.
Dr. Jacqueline Brown talks about current developments in phenotypic precision medicine for prostate cancer.
Jacqueline T. Brown, MD talks about the current state of phenotypic precision medicine for advanced prostate cancer.
The effectiveness of PSMA PET was compared with conventional imaging & liver biopsy, and a radiomic model was also evaluated.
Advertisement
670 Madison Ave.
Manalapan, NJ 07726